12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Urocortin 2: Phase II data

The double-blind, New Zealand Phase II UNICORN trial in 53 patients with ADHF showed that IV urocortin 2 was generally well tolerated with no treatment-related serious adverse events reported. Urocortin 2 significantly reduced mean arterial pressures from baseline to end of infusion...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >